Basis of Presentation and Significant Accounting Policies (Details)			1 Months Ended					3 Months Ended		9 Months Ended		76 Months Ended
	Sep. 15, 2022 USD ($)	Jan. 07, 2020 USD ($)	Dec. 31, 2019 USD ($)	Oct. 31, 2017 USD ($)	May 31, 2017 USD ($)	Jun. 30, 2016 USD ($)	May 31, 2016 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) segment	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)	Oct. 31, 2018	Sep. 30, 2018
Basis of Presentation and Significant Accounting Policies
Accumulated deficit								$ 197,002,176		$ 197,002,176		$ 197,002,176	$ 165,718,953
Net loss								13,094,771	$ 7,548,225	31,548,479	$ 21,791,941
Cash, cash equivalents and short term investments								57,400,000		57,400,000		57,400,000
Derivative warrant liability								274		$ 274		$ 274	11,020
Number of operating segments | segment										1
Revenue Recognition
Revenue								6,039,853	501,567	$ 6,303,252	1,499,706
Allowable expenses incurred under NIH grant								$ 40,000.00	0.0	$ 40,000.00	30,000.00
Other Assets.
Other assets													$ 12,193,540
Shattuck Labs Inc. License Agreement | Shattuck
Deferred Revenue
Initial license fees						$ 50,000
Lab equipment
Other Assets.
Reimbursement of expenses, capitalized	$ 13,200,000
Reimbursements, expensed	900,000
Reimbursement Included in operating lease right of use asset	$ 10,200,000
Pelican Therapeutics, Inc.
Basis of Presentation and Significant Accounting Policies
Ownership interest in subsidiary								85.00%		85.00%		85.00%	85.00%	85.00%	80.00%
Pelican Therapeutics, Inc.
Basis of Presentation and Significant Accounting Policies
Contingent consideration liability, written off								$ 3,100,000
Revenue Recognition
Amount awarded from CPRIT grant							$ 15,200,000
Grant revenue
Revenue Recognition
Revenue								58,860	501,567	$ 322,259	$ 1,499,706
Allowable expenses incurred under NIH grant								40,470	$ 0
Grant revenue | Maximum
Revenue Recognition
Amount awarded from NIH grant		$ 224,713
Grant revenue | Pelican Therapeutics, Inc.
Revenue Recognition
Revenue												$ 15,200,000
Remaining grant amount receivable								$ 1,500,000		$ 1,500,000		$ 1,500,000
Grant revenue | Pelican Therapeutics, Inc. | Maximum
Revenue Recognition
Amount awarded from CPRIT grant						$ 15,200,000
Grant revenue | Tranche 1 | Pelican Therapeutics, Inc.
Revenue Recognition
Revenue					$ 1,800,000
Grant revenue | Tranche 2 | Pelican Therapeutics, Inc.
Revenue Recognition
Revenue				$ 6,500,000
Grant revenue | Tranche 3 | Pelican Therapeutics, Inc.
Revenue Recognition
Revenue			$ 5,400,000